Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
First Claim
1. A method to assess a test compound for its ability to treat a disorder mediated by VCAM-1 comprising evaluating the ability of the compound to inhibit the oxidation of a polyunsaturated fatty acid by the steps of:
- (i) challenging a host to a high level of a polyunsaturated fatty acid and;
(ii) determining the therapeutic efficacy of the test compound based on its ability to decrease the concentration of circulating or cell surface VCAM-1 concentration.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.
68 Citations
11 Claims
-
1. A method to assess a test compound for its ability to treat a disorder mediated by VCAM-1 comprising evaluating the ability of the compound to inhibit the oxidation of a polyunsaturated fatty acid by the steps of:
-
(i) challenging a host to a high level of a polyunsaturated fatty acid and; (ii) determining the therapeutic efficacy of the test compound based on its ability to decrease the concentration of circulating or cell surface VCAM-1 concentration. - View Dependent Claims (3, 4, 5)
-
-
2. A method to assess a test compound for its ability to treat a disorder mediated by VCAM-1 comprising the steps of:
-
(i) exposing a polyunsaturated fatty acid to a protein and the test compound in an in vitro solution in the presence of a substance that is known to oxidize the polyunsaturated fatty acid in the absence of the test compound and; (ii) assessing the extent of interaction between the polyunsaturated fatty acid or oxidized polyunsaturated fatty acid and the protein.
-
-
6. A method to assess a test compound for its ability to treat a disorder mediated by VCAM-1 comprising evaluating the ability of the compound to inhibit the interaction of an oxidized polyunsaturated fatty acid with a protein comprising the steps of:
-
(i) exposing the oxidized polyunsaturated fatty acid to a protein and the test compound in an in vitro solution; (ii) assessing the degree of reaction between the oxidized polyunsaturated fatty acid and the protein. - View Dependent Claims (7)
-
-
8. A method to assess a test compound for its ability to treat a disorder mediated by VCAM-1 comprising evaluating the ability of the compound to inhibit the oxidation of a polyunsaturated fatty acid by the steps of:
-
(i) exposing a polyunsaturated fatty acid to the test compound in an in vitro solution in the presence of a substance that is known to oxidize the polyunsaturated fatty acid in the absence of the test compound and; (ii) assessing the degree of oxidation of the polyunsaturated fatty acid. - View Dependent Claims (9, 10, 11)
-
Specification